Future  	Future  	 JJ	O
aspects  	aspects  	 NNS	O
of  	of  	 IN	O
immunotherapy  	immunotherapy  	 NN	B-NP
and  	and  	 CC	O
gene  	gene  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
neuroblastoma  	neuroblastoma  	 JJ	B-NP
Immunotherapy  	Immunotherapy  	 NNS	I-NP
against  	against  	 IN	O
cancer  	cancer  	 NN	O
aims  	aims  	 VBZ	O
at  	at  	 IN	O
stimulating  	stimulating  	 VBG	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
system  	system  	 NN	O
or  	or  	 CC	O
building  	building  	 VBG	O
an  	an  	 DT	O
immune  	immune  	 JJ	O
response  	response  	 NN	O
against  	against  	 IN	O
targeted  	targeted  	 JJ	O
tumor-associated  	tumor-associated  	 JJ	B-NP
antigens  	antigens  	 NNS	I-NP
( 	( 	 -LRB-	O
TAAs 	TAAs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
proposed  	proposed  	 VBN	O
theoretically  	theoretically  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
potential  	potential  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	O
cancer  	cancer  	 NN	O
over  	over  	 IN	O
a  	a  	 DT	O
century  	century  	 NN	O
ago  	ago  	 RB	O
but  	but  	 CC	O
it  	it  	 PRP	O
became  	became  	 VBD	O
popular  	popular  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
past  	past  	 JJ	O
two  	two  	 CD	O
decades 	decades 	 NNS	O
.  	.  	 .	O
Gene  	Gene  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
represents  	represents  	 VBZ	O
a  	a  	 DT	O
promising  	promising  	 JJ	O
approach  	approach  	 NN	O
for  	for  	 IN	O
reversing  	reversing  	 VBG	O
the  	the  	 DT	O
neoplastic  	neoplastic  	 JJ	B-NP
phenotype  	phenotype  	 NN	I-NP
or  	or  	 CC	O
driving  	driving  	 VBG	B-NP
tumor  	tumor  	 NN	I-NP
cells  	cells  	 NNS	I-NP
to  	to  	 TO	O
self-destruction 	self-destruction 	 JJ	B-NP
.  	.  	 .	O
Although  	Although  	 IN	O
survival  	survival  	 NN	B-NP
rates  	rates  	 NNS	I-NP
of  	of  	 IN	I-NP
neuroblastoma  	neuroblastoma  	 NNS	I-NP
( 	( 	 -LRB-	O
NB 	NB 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
biologically  	biologically  	 JJ	O
favorable  	favorable  	 JJ	O
disease  	disease  	 NN	O
are  	are  	 VBP	O
greater  	greater  	 JJR	O
than  	than  	 IN	O
90 	90 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
outcomes  	outcomes  	 NNS	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
high  	high  	 JJ	O
risk  	risk  	 NN	B-NP
disease  	disease  	 NN	I-NP
are  	are  	 VBP	O
less  	less  	 JJR	O
than  	than  	 IN	O
40 	40 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
Stage  	Stage  	 NNP	O
4  	4  	 CD	O
metastatic  	metastatic  	 JJ	B-NP
NB  	NB  	 NN	I-NP
cases  	cases  	 NNS	I-NP
over  	over  	 IN	O
18  	18  	 CD	O
months  	months  	 NNS	O
of  	of  	 IN	O
age  	age  	 NN	O
are  	are  	 VBP	O
often  	often  	 RB	O
incurable  	incurable  	 VBN	O
with  	with  	 IN	O
multimodality  	multimodality  	 JJ	B-NP
chemotherapy  	chemotherapy  	 JJ	I-NP
regimens 	regimens 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
article 	article 	 NN	O
,  	,  	 ,	O
translation  	translation  	 NN	O
of  	of  	 IN	O
immuno-gene  	immuno-gene  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
strategies  	strategies  	 NNS	I-NP
into  	into  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
for  	for  	 IN	I-NP
NB  	NB  	 NNP	I-NP
are  	are  	 VBP	O
reviewed 	reviewed 	 VBN	O
.  	.  	 .	O
Future  	Future  	 JJ	O
aspects  	aspects  	 NNS	O
of  	of  	 IN	O
immuno-gene  	immuno-gene  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
are  	are  	 VBP	O
discussed 	discussed 	 VBN	O
.  	.  	 .	O
